IDDI provides biostatistical and eClinical services to pharmaceutical and biotech companies since 1991.
Based on the fully human antibody transgenic RenMab™, RenLite™, and RenNano™ Mice, Biocytogen has integrated its technology platforms in single-cell antibody discovery, gene editing, large-scale disease mouse model supply, and in vivo pharmacology screening to form a new approach to streamline the entire antibody drug discovery and development process. Biocytogen collaborates with global partners to accelerate new drug discovery and development. For more information, please visit www.biocytogen.com
Applied BioMath provides mechanistic modeling services to help large and small biotechnology and pharmaceutical companies de-risk therapeutic programs. A team of mathematicians, biologists, clinical pharmacologists and pharmaceutical industry experts, they leverage biology, mathematics, proprietary technologies, HPC, and industry experience to perform massive scale simulations which enable groups to determine best-in-class properties of a clinical candidate, reduce attrition rates, and identify key differentiators from competitors.
Established in 2004, LARVOL combines the best of artificial and human intelligence to deliver expertly curated and personalized data solutions to medical affairs, competitive intelligence, commercial, and R&D teams within the pharmaceutical and biotech industry.
PHC Group develops, manufactures, sells, and services across diabetes management, diagnostics and life sciences, as well as healthcare service businesses. Committed to its corporate mission, “We contribute to the health of society through our diligent efforts to create healthcare solutions that have a positive impact and improve the lives of people,” the company offers value-added products and services to customers in over 125 countries.
We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
Agilent is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications, and expertise, enabling customers to gain the insights they seek. Agilent is providing the entire workflow of target enrichment for different NGS applications such as cancer, infectious and rare diseases. including sample quality control (QC), next-generation sequencing (NGS) library prep and target enrichment, microarrays, CRISPR, PCR/qPCR, bioreagents, and data analysis solutions from interpretation reporting. Furthermore, with the extensive cancer diagnostic and pathology know-how of Agilent Dako, built on more than 50 years of experience, our business of antibodies & assay solutions has established lasting partnerships worldwide with partnering companies, ranging from large multinationals to smaller manufacturers and commercial laboratories specializing in the fields of in vitro diagnostics, biotechnology and pharmaceuticals. Besides the development of companion diagnostic for novel personalized therapy in cancer treatment, collaboration partners also benefit from the high level of familiarity of the Agilent Pathology-portfolio in routine diagnostic.
evorion biotechnologies offers custom development services and access to a unique, proprietary functional phenomics pipeline for in-depth multi-parametric analysis of thousands of cell-cell interactions at single-cell resolution. For the first time, researchers can connect a single cell’s functional phenotype with multi-omics data, opening up a new realm of novel insights into cancer-immune cell interactions that will revolutionize cell therapies. Let us partner in advancing human medicine by developing the next generation of adoptive cell therapies.
Imaging Endpoints (IE) is an imaging research and core laboratory that provides comprehensive imaging CRO services and technology solutions. IE is one of the largest iCROs globally and is widely recognized for conducting the industry’s most complex trials. IE’s experience spans hundreds of successful trials across all phases of development, including the most high-profile, global registration trials. IE also specializes in novel imaging technologies such as radiomics where the company is the industry leader.
TransCure bioServices (TCS) provides predictive in vivo pharmacology expertise for drug pre-clinical candidate selection in the fields of infectious, cancer (IO, PDX), inflammation, vaccine and immune disease areas. We are the only preclinical CRO providing commercially HIV, immuno-oncology (IO) therapy, PDX, IBD, vaccine and autoimmune mouse models with a fully functional reconstituted HUMAN IMMUNE SYSTEM (hu-mouse models). We co-design study protocols/experiments performing the ordered studies and providing comprehensive data collection, data analysis and reports.
Ultivue provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Ultivue’s InSituPlex® technology eliminates the need for assay development and enables scientists to unmask and analyze the true biological context of tissue samples. UltiMapper™ kits are fully optimized mIHC panels that provide uninhibited co-localization of multiple markers for deep single-cell phenotyping.
We are a target discovery and gene editing company utilizing artificial intelligence and our proprietary neural network platform with a therapeutic focus on immuno oncology.
Our proprietary AI target discovery engine is called “Diamond.”
Diamond is AI big data science meeting target identification, dramatically compressing man years and billions of drug development dollars to develop a live drug.
Our first product is Alexis-Pro and Alexis-ISO, off-the-shelf allogenic chPD1, and iso-mesothelin CAR-T(s) for solid tumor.
.png)
Predicine is a molecular insights company committed to advancing biomarker-driven precision medicine. It has developed a breakthrough cell-free DNA and cell-free RNA based liquid biopsy technology for non-invasive cancer profiling, disease monitoring, assessing MRD, and early cancer detection. Predicine partners with leading biopharma companies and hospitals to support global clinical trials and personalized cancer care.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
